Nanobiotix News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

21.10.16	Nanobiotix’s Partner, PharmaEngine, Has Launched a New NBTXR3 Clinical Trial in Head and Neck Cancers in Asia (Businesswire)
20.10.16	Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia (GlobeNewswire)
03.10.16	Nanobiotix Strengthens U.S. Leadership with Appointments of Head of U.S. Clinical Development and Director of Investor Relations (Businesswire)
19.09.16	Bpifrance Grants Nanobiotix a 2M€ Interest-Free Loan to Support Final Development Stage of Lead Product, NBTXR3 (Businesswire)
19.09.16	Bpifrance grants Nanobiotix a 2M€ interest-free loan to support final development stage of lead product, NBTXR3 (GlobeNewswire)
13.09.16	Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe (GlobeNewswire)
13.09.16	Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe (Businesswire)
31.08.16	Nanobiotix Half Year Results for the Six Months Ended 30 June 2016 (Businesswire)
13.07.16	Nanobiotix Revenue for Q2 2016 (Businesswire)
06.07.16	Nanobiotix Reports Successful Results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer (Businesswire)
06.07.16	Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer (GlobeNewswire)
14.06.16	Nanobiotix Announces Exercise of Warrants by Capital Venture International (Businesswire)
31.05.16	Nanobiotix Receives US$1m Milestone Payment from PharmaEngine (Businesswire)
31.05.16	Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology (GlobeNewswire)
31.05.16	Nanobiotix Establishes Promising Preclinical Proof-of-Concept in Immuno Oncology (Businesswire)
13.05.16	Nanobiotix revenue for the 1st quarter of 2016 (Businesswire)
29.04.16	Nanobiotix: 2015 Annual Results (GlobeNewswire)
29.04.16	Nanobiotix: 2015 Annual Results (Businesswire)
11.03.16	Nanobiotix Completes a EUR 21.3 Million Private Placement of New Ordinary Shares (Businesswire)
26.02.16	Nanobiotix 2015 Q4 and Annual Revenues (Businesswire)
05.01.16	Nanobiotix Starts a New Research Program, in Immuno Oncology, with Its Lead Product NBTXR3 (Businesswire)
04.01.16	Nanobiotix: FDA Approved Investigational New Drug for NBTXR3 in a New Clinical Study in Prostate Cancer (Businesswire)
04.01.16	NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer (GlobeNewswire)
13.11.15	Nanobiotix Revenue for Q3 2015 (Businesswire)
13.11.15	Nanobiotix’s Soft Tissue Sarcoma Pivotal Trial Progressing Well as Planned: Already 7 Countries and 29 Sites Opened (Businesswire)
13.11.15	Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened (GlobeNewswire)
27.08.15	Nanobiotix Half Year Results for the Six Months Ended 30 June 2015, in Line with Expectations (Businesswire)
15.07.15	Nanobiotix revenue for Q2 2015 (Businesswire)
01.07.15	Nanobiotix starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 (Businesswire)
01.07.15	NANOBIOTIX :starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3 (GlobeNewswire)
10.06.15	NANOBIOTIX :reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 (GlobeNewswire)
09.06.15	Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 (Businesswire)
13.05.15	CORRECTING and REPLACING: Nanobiotix revenue for the 1st quarter of 2015 (Businesswire)
13.05.15	Nanobiotix Revenue for the 1st Quarter of 2015 (Businesswire)
11.05.15	Nanobiotix Expands Soft Tissue Sarcoma Pivotal Clinical Trial across Europe and Beyond, According to Plan (Businesswire)
14.04.15	Nanobiotix: 2014 Annual Results (Businesswire)
14.04.15	NANOBIOTIX : 2014 ANNUAL RESULTS (GlobeNewswire)
17.03.15	Nanobiotix Appoints Its Manufacturing Partner, CordenPharma : Another Step Towards Commercialization (Businesswire)
27.02.15	Nanobiotix 2014 Q4 and Annual Revenues (Businesswire)
19.02.15	Professor Robert Langer joins Nanobiotix as Scientific Advisor (GlobeNewswire)
19.02.15	Professor Robert Langer joins Nanobiotix as Scientific Advisor (Businesswire)
27.01.15	Nanobiotix Shares Transferred from Compartment C to Compartment B of the Regulated Market of Euronext in Paris (Businesswire)
01.12.14	Nanobiotix Places Shares and Warrants with US Investor (Businesswire)
14.11.14	Nanobiotix: Revenue for the 3rd Quarter of 2014 (Businesswire)
16.10.14	Nanobiotix Receives First Approval to Start Phase II/III Registration Trial in Soft Tissue Sarcoma in Europe (Businesswire)
16.10.14	Nanobiotix Receives First Approval to Start Phase II/III Registration Trial in Soft Tissue Sarcoma in Europe (Businesswire)
16.10.14	Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe (GlobeNewswire)
08.10.14	PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific (GlobeNewswire)
22.09.14	Nanobiotix Expands Operations into the USA as Part of Its International Development Strategy (Businesswire)
22.09.14	Nanobiotix Expands Operations into the USA as Part of Its International Development Strategy (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Nanobiotix SA

Aktien Top/Flop

Meistgelesene Nachrichten